Advertisement

Topics

Genentech Announces New OCREVUS (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of Two Global Studies in Progressive MS

01:00 EDT 14 Jun 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
OCREVUS may delay the need for a wheelchair by seven years for people with primary progressive multiple sclerosis (PPMS) Longer-term efficacy and safety data are consistent with OCREVUS’ favorable b...

Other Sources for this Article

Genentech
Media Contact:
Kimberly Muscara, 650-467-6800
or
Advocacy Contact:
Jo Dulay, 202-316-6304
or
Investor Contact:
Loren Kalm, 650-225-3217
Karl Mahler, 011 41 61 687 8503

NEXT ARTICLE

More From BioPortfolio on "Genentech Announces New OCREVUS (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of Two Global Studies in Progressive MS"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...